Mineralys Therapeutics (NASDAQ:MLYS) Posts Earnings Results

Mineralys Therapeutics (NASDAQ:MLYS) released its quarterly earnings results on Wednesday. The company reported ($2.85) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($2.30), FiscalAI reports.

Mineralys Therapeutics Trading Down 1.0%

MLYS opened at $27.05 on Thursday. Mineralys Therapeutics has a 12 month low of $12.59 and a 12 month high of $47.65. The business’s 50-day moving average price is $26.42 and its 200-day moving average price is $27.60. The company has a market cap of $2.23 billion, a P/E ratio of -6.38 and a beta of 0.68.

Insider Buying and Selling

In other news, insider David Malcom Rodman sold 2,170 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $27.09, for a total transaction of $58,785.30. Following the completion of the transaction, the insider directly owned 51,384 shares of the company’s stock, valued at approximately $1,391,992.56. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Daphne Karydas sold 3,000 shares of the stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $25.00, for a total transaction of $75,000.00. Following the sale, the director owned 6,200 shares of the company’s stock, valued at approximately $155,000. This represents a 32.61% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 217,313 shares of company stock worth $5,624,488. 18.94% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. RA Capital Management L.P. lifted its holdings in Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock worth $277,717,000 after buying an additional 1,176,470 shares during the period. State Street Corp increased its stake in shares of Mineralys Therapeutics by 144.4% during the fourth quarter. State Street Corp now owns 3,184,999 shares of the company’s stock valued at $115,584,000 after buying an additional 1,881,976 shares during the period. Caligan Partners LP raised its holdings in shares of Mineralys Therapeutics by 37.4% during the third quarter. Caligan Partners LP now owns 2,772,654 shares of the company’s stock valued at $105,139,000 after acquiring an additional 755,302 shares in the last quarter. Franklin Resources Inc. lifted its stake in Mineralys Therapeutics by 0.3% in the third quarter. Franklin Resources Inc. now owns 1,809,768 shares of the company’s stock worth $68,626,000 after acquiring an additional 6,171 shares during the period. Finally, Orbimed Advisors LLC lifted its stake in Mineralys Therapeutics by 93.3% in the third quarter. Orbimed Advisors LLC now owns 1,469,494 shares of the company’s stock worth $55,723,000 after acquiring an additional 709,143 shares during the period. Hedge funds and other institutional investors own 84.46% of the company’s stock.

Key Headlines Impacting Mineralys Therapeutics

Here are the key news stories impacting Mineralys Therapeutics this week:

• Positive Sentiment: FDA decision and launch preparations remain on track: Mineralys reiterated the December 22, 2026 PDUFA target date for lorundrostat, its investigational hypertension treatment, and said commercial preparations are progressing ahead of a potential approval. Mineralys second-quarter results and corporate update
• Positive Sentiment: Cash runway and product economics improved: Management said its cash position should fund operations into 2028. Strategic financing actions and the repurchase of the Tanabe royalty obligation could reduce future royalty costs and improve lorundrostat’s commercial economics. Mineralys launch readiness and cash runway
• Positive Sentiment: Analyst remains bullish despite estimate reduction: HC Wainwright lowered its fiscal 2030 EPS estimate to $3.41 from $3.73 but maintained a Buy rating, indicating continued confidence in the longer-term opportunity. Mineralys analyst estimates
• Neutral Sentiment: Insider sale was conducted under a trading plan: Director David Malcom Rodman sold 2,170 shares for approximately $58,785, reducing his position by 4.05%. Because the sale occurred under a pre-arranged Rule 10b5-1 plan, it may provide limited insight into management’s current outlook.
• Negative Sentiment: Quarterly loss significantly missed expectations: Mineralys reported a second-quarter loss of $2.85 per share versus the consensus estimate of a $0.55 loss. The sizable earnings shortfall may pressure the stock, particularly while the company remains pre-commercial and dependent on lorundrostat’s regulatory outcome. Mineralys second-quarter earnings call transcript

Analysts Set New Price Targets

A number of brokerages recently commented on MLYS. Jefferies Financial Group reaffirmed a “hold” rating on shares of Mineralys Therapeutics in a research report on Monday, June 1st. HC Wainwright restated a “buy” rating on shares of Mineralys Therapeutics in a research note on Monday, June 1st. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mineralys Therapeutics in a research report on Friday, July 17th. TD Cowen started coverage on Mineralys Therapeutics in a research note on Monday, April 27th. They issued a “buy” rating on the stock. Finally, Wall Street Zen cut Mineralys Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Six research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Mineralys Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $49.33.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.